Τίτλος:
Correlation of patient preferences to treatment outcomes in patients with rheumatoid arthritis treated with tumour necrosis factor inhibitors in Greece
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Objectives: To investigate possible associations between rheumatoid arthritis (RA) patient-expressed preferences over anti-tumour necrosis factor (anti-TNF) treatment and clinical and patient-reported outcomes. Methods: PANORAMA was a non-interventional, prospective, multicentre, cohort study of 12 months duration, in patients with moderate-to-severe RA who initiated or switched to anti-TNF treatment. After initiation of anti-TNF, patients completed a preferences questionnaire on attributes related to anti-TNF treatment. Satisfaction with treatment was assessed with the Treatment Satisfaction Questionnaire for Medication (TSQM); compliance and persistence to treatment were recorded via a patient diary. Univariate and multivariate analyses were applied to assess correlations between patients’ preferences over treatment with clinical and patient-reported outcomes. Results: A total of 254 patients were enrolled; 66.1% (168/254) had highly active disease (DAS28-ESR > 5.1), while 65.4% (166/254) were biological-naïve. The 12-month drug-survival rate was 72.3%, while the respective rates of good EULAR response and remission (DAS28-ESR < 2.6) were 56.5% and 40.8%, respectively. By univariate analysis, fulfilment of patient preferences over treatment was associated with increased probability of remaining on therapy (p = 0.019), good EULAR response (p < 0.001) and satisfaction with treatment (p < 0.001). By multivariate analysis, fulfilment of patient preferences was the most important predictor for good EULAR response (OR 5.56, p < 0.001; finding confirmed and after propensity scoring matching), while seropositivity (HR 1.18, p = 0.047) and a high ESR (> 35 mm/h, HR 1.16, p = 0.071) predicted drug survival. Conclusions: In anti-TNF-treated RA patients, fulfilment of treatment preferences was independently associated with a good EULAR response and correlated with drug persistence at 12 months, emphasising the importance of patient preferences in treatment outcomes.Key Points• In anti-TNF treated RA patients, fulfilment of patients’ treatment preferences is associated with a good clinical response at 12 months.• A shared decision-making process can maximise treatment’s outcome in anti-TNF treated patients. © 2020, International League of Associations for Rheumatology (ILAR).
Συγγραφείς:
Sidiropoulos, P.
Bounas, A.
Athanassiou, P.
Koutsianas, C.
Petrikkou, E.
Kaltsonoudis, E.
Drosos, A.
Vassilopoulos, D.
Περιοδικό:
Bailliere's Clinical Rheumatology
Εκδότης:
Springer Science and Business Media Deutschland GmbH
Λέξεις-κλειδιά:
adalimumab; certolizumab pegol; corticosteroid; disease modifying antirheumatic drug; etanercept; golimumab; hydroxychloroquine; infliximab; leflunomide; methotrexate; nonsteroid antiinflammatory agent; tumor necrosis factor inhibitor; antirheumatic agent; tumor necrosis factor; tumor necrosis factor inhibitor, adult; Article; attitude to health; clinical outcome; cohort analysis; comorbidity; DAS28; disease duration; drug safety; drug tolerability; drug withdrawal; female; follow up; Greece; human; major clinical study; male; middle aged; multicenter study; patient compliance; patient preference; patient satisfaction; patient-reported outcome; priority journal; prospective study; remission; rheumatoid arthritis; shared decision making; survival rate; swollen joint count; tender joint count; treatment response; patient preference; treatment outcome, Antirheumatic Agents; Arthritis, Rheumatoid; Cohort Studies; Greece; Humans; Patient Preference; Prospective Studies; Treatment Outcome; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha
DOI:
10.1007/s10067-020-05171-8
